Sight Sciences (SGHT) Cash & Equivalents (2020 - 2026)

Sight Sciences' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $85.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 21.89% year-over-year to $85.0 million; the TTM figure through Mar 2026 stood at $85.0 million (down 21.89% YoY), while the FY2025 annual figure was $92.0 million, down 23.59% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $85.0 million, down from $92.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $238.6 million in Q1 2022, with the low at $85.0 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $127.3 million (2024), against an average of $141.9 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents jumped 518.74% in 2022, then slipped 29.86% in 2023.
• Sight Sciences' Cash & Equivalents stood at $185.0 million in 2022, then decreased by 25.34% to $138.1 million in 2023, then decreased by 12.87% to $120.4 million in 2024, then declined by 23.59% to $92.0 million in 2025, then decreased by 7.61% to $85.0 million in 2026.
• Business Quant data shows SGHT's Cash & Equivalents at $85.0 million in Q1 2026, $92.0 million in Q4 2025, and $92.4 million in Q3 2025.